HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
NEW YORK, Oct. 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0652040/HIV/AIDS-Therapeutics-Market-to-2017---Superior-Combination-Therapies-and-Decreasing-Mortality-to-Sustain-Market-Growth-Despite-Major-Patent-Expiries.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
Summary
GBI Research, the leading business intelligence provider, has released its latest research, "HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries". It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the markets for HIV/AIDS in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage pattern and annual cost of treatment are forecast until 2017 for key geographies in the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Scope
The scope of this report includes -
- Annualized market data for the HIV therapeutics market from 2002 to 2010, forecast until 2017.
- Analysis of the HIV therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align product portfolio to the markets with high growth potential.
- Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7
2 HIV/AIDS Therapeutics Market to 2017 - Introduction 9
2.1 GBI Research Report Guidance 9
3 HIV/AIDS Therapeutics Market to 2017 - Global Overview 10
3.1 Disease Overview 10
3.2 Market Overview 12
3.3 Overview of Recent Research Advancements in HIV/AIDS Therapy 13
4 HIV/AIDS Therapeutics Market to 2017 - Market Characterization 14
4.1 Market Forecasts 14
4.1.1 Branded Versus Generics 15
4.2 Annual Cost of Therapy 16
4.3 Treatment Usage Patterns 17
4.3.1 Diseased Population 19
4.3.2 Treatment Seeking Population 21
4.3.3 Diagnosis Population 22
4.3.4 Prescription Population 24
4.4 Geographical Distribution 25
4.5 Drivers and Restraints 26
4.6 Market Drivers 27
4.6.1 Increase in Awareness Levels of Disease Progression will Lead to an Increase in Treatment Seeking and Diagnosed Populations 27
4.6.2 New Product Launches will Increase Uptake and Drive the Market 28
4.6.3 Increase in Drug Prices will Drive Growth and Lessen the Impact of Generics 29
4.7 Market Restraints 30
4.7.1 Patent Expirations and the Subsequent Entry of Generics will Negatively Impact the Market 30
4.7.2 Social Stigma Associated with HIV Leads to Low Treatment Seeking Rate 31
4.7.3 Rigorous and Complex Treatment Regimes Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes 31
5 HIV/AIDS Therapeutics Market to 2017 - The US 32
5.1 Market Forecasts 32
5.2 Annual Cost of Therapy 33
5.3 Treatment Usage Patterns 34
5.3.1 Diseased Population 36
5.3.2 Treatment Seeking Population 37
5.3.3 Diagnosis Population 38
5.3.4 Prescription Population 40
6 HIV/AIDS Therapeutics Market to 2017- Top Five European Countries 42
6.1 Market Forecasts 42
6.1.1 Revenue by Country 44
6.2 Annual Cost of Therapy 45
6.3 Treatment Usage Patterns 46
6.3.1 Diseased Population 48
6.3.2 Treatment Seeking Population 49
6.3.3 Diagnosis Population 50
6.3.4 Prescription Population 52
7 HIV/AIDS Therapeutics Market to 2017 - Japan 53
7.1 Market Forecasts 53
7.2 Annual Cost of Therapy 54
7.3 Treatment Usage Patterns 55
7.3.1 Diseased Population 57
7.3.2 Treatment Seeking Population 58
7.3.3 Diagnosis Population 59
7.3.4 Prescription Population 60
8 HIV/AIDS Therapeutics Market to 2017 - Pipeline Assessment 62
8.1 Major Classes of Drugs 62
8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 62
8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 62
8.1.3 Protease Inhibitors 64
8.1.4 Viral Fusion (or Entry) Inhibitors 64
8.1.5 HIV Integrase Strand Transfer Inhibitors 64
8.1.6 Multi-Class Combination Products 64
8.2 Pipeline Overview 64
8.3 Strategic Pipeline Assessment 65
8.4 HIV/AIDS Therapeutics Pipeline - Pipeline by Clinical Phases of Development 65
8.4.1 HIV/AIDS Therapeutics - Phase III Clinical Pipeline 65
8.4.2 HIV/AIDS Therapeutics - Phase II Clinical Pipeline 66
8.4.3 HIV/AIDS Therapeutics - Phase I Clinical Pipeline 67
8.4.4 HIV/AIDS - Preclinical Pipeline 68
8.4.5 HIV/AIDS - Discovery Clinical Pipeline 69
8.5 HIV/AIDS Therapeutics - Pipeline by Mechanism of Action 70
8.6 HIV/AIDS Therapeutics - Most Promising Drugs under Clinical Development 71
9 HIV/AIDS Therapeutics Market to 2017 - Competitive Landscape 72
9.1 Major Company Profiles 73
9.1.1 Gilead Sciences, Inc 74
9.1.2 GlaxoSmithKline (GSK) 76
9.1.3 Bristol-Myers Squibb (BMS) 78
9.1.4 Abbott Laboratories 80
9.1.5 Merck 82
9.1.6 Pfizer 84
10 HIV/AIDS Therapeutics Market to 2017 - Licencing and Partnership Deals 85
10.1 Global HIV/AIDS Market 85
10.1.1 Overview: Deals by Type and Geography 85
10.1.2 Mergers and Acquisitions 86
10.1.3 Licensing Agreements 87
11 HIV/AIDS Therapeutics Market to 2017 - Appendix 91
11.1 Market Definitions 91
11.2 Abbreviations 91
11.3 Research Methodology 92
11.3.1 Coverage 92
11.3.2 Secondary Research 92
11.3.3 Primary Research 93
11.3.4 Forecasts 93
11.3.5 Expert Panel Validation 95
11.4 Contact Us 96
11.5 Disclaimer 96
11.6 Sources 96
1.1 List of Tables
Table 1: HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002-2010 14
Table 2: HIV/AIDS Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 14
Table 3: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 16
Table 4: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 16
Table 5: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns ('000), 2002-2010 18
Table 6: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns ('000), 2010-2017 18
Table 7: HIV/AIDS Therapeutics Market, Global, Diseased Population ('000), 2002-2010 20
Table 8: HIV/AIDS Therapeutics Market, Global, Diseased Population ('000), 2010-2017 20
Table 9: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population ('000), 2002-2010 21
Table 10: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population ('000), 2010-2017 21
Table 11: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2002-2010 23
Table 12: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2010-2017 23
Table 13: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2002-2010 24
Table 14: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2010-2017 25
Table 15: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2002-2010 25
Table 16: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2010-2017 26
Table 17: HIV/AIDS Therapeutics Market, Global, Key Drugs Going Off Patent, 2009-2017 30
Table 18: HIV/AIDS Therapeutics Market, the US, Revenues ($m), 2002-2010 32
Table 19: HIV/AIDS Therapeutics Market, the US, Revenue ($m), 2010-2017 32
Table 20: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2010 33
Table 21: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2010-2017 33
Table 22: HIV/AIDS Therapeutics Market, the US, Treatment Usage Patterns ('000), 2002-2010 35
Table 23: HIV/AIDS Therapeutics Market, US, Treatment Usage Patterns ('000), 2010-2017 35
Table 24: HIV/AIDS Therapeutics Market, the US, Diseased Population ('000), 2002-2010 36
Table 25: HIV/AIDS Therapeutics Market, the US, Diseased Population ('000), 2010-2017 37
Table 26: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population ('000), 2002-2010 38
Table 27: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population ('000), 2010-2017 38
Table 28: HIV/AIDS Therapeutics Market, US, Diagnosis Population ('000), 2002-2010 39
Table 29: HIV/AIDS Therapeutics Market, US, Diagnosis Population ('000), 2010-2017 39
Table 30: HIV/AIDS Therapeutics Market, the US, Prescription Population ('000), 2002-2010 41
Table 31: HIV/AIDS Therapeutics Market, the US, Prescription Population ('000), 2010-2017 41
Table 32: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenues ($m), 2002-2010 43
Table 33: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenues ($m), 2010-2017 43
Table 34: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country ($m), 2002-2010 44
Table 35: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country ($m), 2010-2017 44
Table 36: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2002-2010 45
Table 37: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2010-2017 46
Table 38: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage Patterns, 2002-2010 47
Table 39: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage Patterns, 2010-2017 47
Table 40: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population ('000), 2002-2010 48
Table 41: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population ('000), 2010-2017 48
Table 42: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Seeking Population ('000), 2002-2010 49
Table 43: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Seeking Population ('000), 2010-2017 49
Table 44: HIV/AIDS Therapeutics Market, Top Five European Countries, Diagnosis Population ('000), 2002-2010 51
Table 45: HIV/AIDS Therapeutics Market, Top Five European Countries, Diagnosis Population ('000), 2010-2017 51
Table 46: HIV/AIDS Therapeutics Market, Top Five European Countries, Prescription Population ('000), 2002-2010 52
Table 47: HIV/AIDS Therapeutics Market, Top Five European Countries, Prescription Population ('000), 2010-2017 52
Table 48: HIV/AIDS Therapeutics Market, Japan, Revenues ($m), 2002-2010 54
Table 49: HIV/AIDS Therapeutics Market, Japan, Revenues ($m), 2010-2017 54
Table 50: HIV/AIDS Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 55
Table 51: HIV/AIDS Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 55
Table 52: HIV/AIDS Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2002-2010 56
Table 53: HIV/AIDS Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2010-2017 56
Table 54: HIV/AIDS Therapeutics Market, Japan, Diseased Population ('000), 2002-2010 57
Table 55: HIV/AIDS Therapeutics Market, Japan, Diseased Population ('000), 2010-2017 57
Table 56: HIV/AIDS Therapeutics Market, Japan, Treatment Seeking Population ('000), 2002-2010 58
Table 57: HIV/AIDS Therapeutics Market, Japan, Treatment Seeking Population ('000), 2010-2017 58
Table 58: HIV/AIDS Therapeutics Market, Japan, Diagnosis Population ('000), 2002-2010 59
Table 59: HIV/AIDS Therapeutics Market, Japan, Diagnosis Population ('000), 2010-2017 59
Table 60: HIV/AIDS Therapeutics Market, Japan, Prescription Population ('000), 2002-2010 60
Table 61: HIV/AIDS Therapeutics Market, Japan, Prescription Population ('000), 2010-2017 61
Table 62: HIV/AIDS Therapeutics Market, Global, Different Classes of Drugs 63
Table 63: HIV/AIDS Therapeutics Market, Phase III Pipeline, 2010 65
Table 64: HIV/AIDS Therapeutics Market, Phase II Pipeline, 2010 66
Table 65: HIV/AIDS Therapeutics Market, Phase I Pipeline, 2010 67
Table 66: HIV/AIDS Therapeutics Market, Preclinical Pipeline, 2010 68
Table 67: HIV/AIDS Therapeutics Market, Discovery Clinical Pipeline, 2010 69
Table 68: HIV/AIDS Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010 71
Table 69: HIV/AIDS Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2010 73
Table 70: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2009 88
Table 71: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Drugs in Phase II, 2009 89
Table 72: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Drugs in Phase III, 2009 89
Table 73: HIV/AIDS Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2009 90
1.2 List of Figures
Figure 1: HIV/AIDS Therapeutics Market, Global, HIV Treatment Flow Algorithm, 2011 11
Figure 2: HIV/AIDS Therapeutics Market, Global, Market Overview, 2010 12
Figure 3: HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002-2017 14
Figure 4: HIV/AIDS Therapeutics Market, Global, Revenue Segmentation, 2010-2017 15
Figure 5: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 16
Figure 6: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns, 2002-2017 17
Figure 7: HIV/AIDS Therapeutics Market, Global, Diseased Population, 2002-2017 19
Figure 8: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population, 2002-2017 21
Figure 9: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2002-2017 23
Figure 10: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2002-2017 24
Figure 11: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2002-2017 25
Figure 12: HIV/AIDS Therapeutics Market, the US, Revenue ($m), 2002-2017 32
Figure 13: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2017 33
Figure 14: HIV/AIDS Therapeutics Market, the US, Treatment Usage Patterns, 2002-2017 34
Figure 15: HIV/AIDS Therapeutics Market, the US, Diseased Population, 2002-2017 36
Figure 16: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population, 2002-2017 37
Figure 17: HIV/AIDS Therapeutics Market, US, Diagnosis Population, 2002-2017 38
Figure 18: HIV/AIDS Therapeutics Market, the US, Prescription Population, 2002-2017 40
Figure 19: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue ($m), 2002-2017 43
Figure 20: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country ($m), 2002-2017 44
Figure 21: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2002-2017 45
Figure 22: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage Patterns, 2002-2017 46
Figure 23: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population, 2002-2017 48
Figure 24: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Seeking Population, 2002-2017 49
Figure 25: HIV/AIDS Therapeutics Market, Top Five European Countries, Diagnosis Population, 2002-2017 50
Figure 26: HIV/AIDS Therapeutics Market, Top Five European Countries, Prescription Population, 2002-2017 52
Figure 27: HIV/AIDS Therapeutics Market, Japan, Revenue ($m), 2002-2017 53
Figure 28: HIV/AIDS Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017 54
Figure 29: HIV/AIDS Therapeutics Market, Japan, Treatment Usage Patterns, 2002-2017 55
Figure 30: HIV/AIDS Therapeutics Market, Japan, Diseased Population, 2002-2017 57
Figure 31: HIV/AIDS Therapeutics Market, Japan, Treatment Seeking Population, 2002-2017 58
Figure 32: HIV/AIDS Therapeutics Market, Japan, Diagnosis Population, 2002-2017 59
Figure 33: HIV/AIDS Therapeutics Market, Japan, Prescription Population, 2002-2017 60
Figure 34: HIV/AIDS Therapeutics Market, Pipeline by Phases of Development (%), 2010 65
Figure 35: HIV/AIDS Therapeutics Market, Pipeline by Mechanism of Action (%), 2010 70
Figure 36: HIV/AIDS Therapeutics Market, Global, Competitive Analysis of Major Manufacturers, Revenues, 2008-2010 72
Figure 37: HIV/AIDS Therapeutics Market, Gilead, HIV Revenue as Percentage of Total Revenue, 2010 74
Figure 38: HIV/AIDS Therapeutics Market, Gliead Sciences Ic, SWOT Analysis, 2010 75
Figure 39: HIV/AIDS Therapeutics Market, GlaxoSmithKline, HIV Revenue as Percentage of Total Revenue, 2010 76
Figure 40: HIV/AIDS Therapeutics Market, GlaxoSmithKline, SWOT Analysis, 2010 77
Figure 41: HIV/AIDS Therapeutics Market, Bristol-Myers-Squibb, HIV Revenue as Percentage of Total Revenue, 2010 78
Figure 42: HIV/AIDS Therapeutics Market, Bristol-Myers Squibb, SWOT Analysis, 2010 79
Figure 43: HIV/AIDS Therapeutics Market, Abbott, HIV Revenue as Percentage of Total Revenue, 2010 80
Figure 44: HIV/AIDS Therapeutics Market, Abbott Laboratories, SWOT Analysis, 2010 81
Figure 45: HIV/AIDS Therapeutics Market, Merck, HIV Revenue as Percentage of Total Revenue, 2010 82
Figure 46: HIV/AIDS Therapeutics Market, Merck, SWOT Analysis, 2010 83
Figure 47: HIV/AIDS Therapeutics Market, Pfizer, SWOT Analysis, 2010 84
Figure 48: HIV/AIDS Therapeutics Market, Global, Deals by Geography and Type, 2009-2010 85
Figure 49: HIV/AIDS Therapeutics Market, Global, M&A Deals, 2009-2010 86
Figure 50: HIV/AIDS Therapeutics Market, Global, Major Licensing Agreements by Phase, 2009-2010 87
Figure 51: GBI Research Market Forecasting Model 95
Companies mentioned
Gilead Sciences, Inc
GlaxoSmithKline (GSK)
Bristol-Myers Squibb (BMS)
Abbott Laboratories
Merck
Pfizer
To order this report:
Pathology Industry: HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
Pathology Business News
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article